Analytical Data
-
Gene name
CD27
- Application
-
Alternative Names
CD27; TNFRSF7; CD27 antigen; CD27L receptor; T-cell activation antigen CD27; T14; Tumor necrosis factor receptor superfamily member 7; CD antigen CD27
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P26842
-
Expression Region
1-260aa
-
AA Sequence
MARPHPWWLCVLGTLVGLSATPAPKSCPERHYWAQGKLCCQMCEPGTFLVKDCDQHRKAAQCDPCIPGVSFSPDHHTRPHCESCRHCNSGLLVRNCTITANAECACRNGWQCRDKECTECDPLPNPSLTARSSQALSPHPQPTHLPYVSEMLEARTAGHMQTLADFRQLPARTLSTHWPPQRSLCSSDFIRILVIFSGMFLVFTLAGALFLHQRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSP
-
Molecular Weight
29.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD27 is a member of the Tumor Necrosis Factor Receptor (TNFR) superfamily, playing a crucial role in the regulation of immune responses and T-cell activation. It is primarily expressed on the surface of T-lymphocytes and is involved in various immune functions, including cell proliferation, differentiation, and survival. Research into CD27 has gained momentum due to its potential implications in immunotherapy and the treatment of cancers and autoimmune diseases. The discovery of CD27 as a co-stimulatory molecule has highlighted its importance in enhancing T-cell responses when engaged by its ligand, CD70. This interaction is critical for the survival and clonal expansion of T-cells, making CD27 a promising target for therapeutic intervention. Recombinant CD27 proteins have been developed to study its biological functions in vitro and in vivo, as well as to explore its potential as a biomarker for immune-related diseases. The ability to produce high-quality CD27 recombinant proteins is vital for evaluating their properties and effects in various experimental settings, including cellular assays and therapeutic applications. Investigating CD27 in the context of cancer immunotherapy is particularly appealing, as it may facilitate the enhancement of anti-tumor immune responses and improve the efficacy of existing treatment modalities. Consequently, ongoing research aims to elucidate the mechanisms of CD27 signaling, its interactions with other immune molecules, and its overall impact on the immune landscape, paving the way for innovative strategies to harness this receptor in clinical settings.
